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Summary 
Dissection of the peptide binding grooves of seven subtypes of human histocompatibility  leukocyte 
antigen (HLA)-B27 into the six specificity pockets defined by the 2.6-A structure of HLA- 
?,'0201 revealed just one pocket, the B ("45") pocket, that is conserved among all the HLA-B27 
subtypes. Functional studies of mutant HLA-B*2705 molecules with point substitutions in residues 
of the B pocket show that this structure, and the glutamine residue at position 45 in particular, 
plays a critical role in cell surface expression,  peptide binding, and in the presentation of both 
exogenous and endogenous peptides by HLA-B*2705. We predict that the B pocket of HLA- 
B'2705 interacts with an amino acid side chain that anchors peptides in the binding groove, 
and that this peptide motif is present in most endogenously processed  peptides that bind to 
all seven subtypes of HLA-B27. 
H 
LA class I molecules bind and present antigenic pep- 
tides to CTLs (1, 2). Bound peptides form an integral 
part of the molecule and facilitate  stable expression  at the 
cell surface (3, 4).  Antigenic peptides eluted from murine 
H-2 class I molecules and HLA-A*0201  have been sequenced. 
These analyses reveal that naturally processed  peptides are 
generally heterogenous in character but restricted in length 
to eight or nine amino acid residues. Furthermore, for any 
given allele certain peptide residues show limited heteroge- 
neity, allowing the definition of allele-specific  sequence motifs 
in terms of these "anchor" residues  (5-8).  Examination of 
the structure of antigenic peptides, represented as "extra den- 
sity" in the x-ray crystallographic solutions for HLA-A*0201 
and A'6801, suggests that the peptide amino acid side chains 
are positioned in the dass I molecule to interact with specificity 
pockets that extend from the peptide binding groove (9-11). 
In light of these findings, we reasoned that peptide anchor 
residues must interact with class I molecules through specificity 
pockets that are optimized to bind their side chains, and other 
residue side chains may interact with pockets that are less 
discriminating. Pockets binding anchoring side chains would 
be specialized structures within the peptide binding groove 
that  might  be  maintained  during  evolution  because  of 
their important functional role. To test this hypothesis, we 
first examined the primary structures of 61 HLA class I mol- 
ecules and mapped their'polymorphisms into the six speci- 
ficity  ~  pockets revealed in the peptide binding groove of the 
2.6-Arefined structure of HLA-A*0201 (11, 12). This anal- 
ysis demonstrated that all six pockets contain highly poly- 
morphic residues and that there is little tendency for major 
alleles to share similar pocket structures (data not shown). 
We then chose to examine the subtypes of major alleles, as 
products of relatively  recent evolutionary change. 
We report our findings with respect  to seven HLA-B27 
subtypes (12-14). Sequence comparison reveals eleven residues 
that are polymorphic among the subtypes, and these map 
to five of the six specificity pockets. One pocket, the B ("45") 
pocket, is totally conserved among all HLA-B27 subtypes. 
Further analysis by site-directed  mutagenesis shows this re- 
gion, and the glutamine residue at position 45 in particular, 
play a critical role in cell-surface expression, peptide binding, 
and antigen presentation by HLA-B*2705. We predict that 
the B pocket binds an anchor residue found in most HLA- 
B'2705 binding peptides, and that this represents a peptide 
motif that is likely to be shared by all the HLA-B27 subtypes. 
Materials and Methods 
Cells.  PBL were obtained  from Caucasian HLA-B*2705-positive 
male volunteers, and EBV-transformed  B cell lines were made for 
use as autologous feeder cells in the generation of peptide-specific 
CTL lines. HLA types of CTL  lines used were: RB  (A2,32; 
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BwS0,Bw55; Cw3,Cw6). Other EBV lines used were: JY (A2,2; 
B7,7;), BL,  EBV (A1,2;BT,37), HOM2 (A3; B'2705), JESTHOM 
(A2; B'2705),  C1R (  ,  , Cw4), B27CIK (-, B'2705,  Cw4), 
LH (A24; B'2701,8; Cwl,7), PG (All,31;  B'2705,35;  Cw2,4), 
WE1 (All,24;  B*2704,w62; Cw6),  and LIE (A2,11; B'2706,5; 
Cw3). 
Mutagenesis and Transfection.  HLA-B27  single residue mutants 
(see Table 3) were created by site-directed  mutagenesis of the HLA- 
B'2705 gene obtained from Dr. Joel Tautog (University of Texas 
Southwestern  Medical  Center, Dallas, TX), as a 6.5-kb EcoRI frag- 
ment subcloned  in pUC19. Three constructs were made. First, the 
HLA-B*2705 gene was shortened in the 3' untranslated region by 
restriction enzyme digestion with BstEII and HinclI (in the 3' poly- 
linker of pUC19), Klenow DNA polymerase I fill  in, and subse- 
quent religation. This served to shorten the gene to 3.9 kb and 
to remove an inconvenient second 3' DralII site. Next the exons 
encoding the leader sequence, c~ and c~2 domains were subcloned 
as a 2-kb EcoR.I/AvrlI fragment into EcoRI/XbaI cut M13mp18 
vector, and the exons encoding the c~3, transmembrane, and cyto- 
plasmic domains were subcloned as a 2.2-kb KpnI/Sspl fragment 
into KpnI/HinclI cut M13mp18. Mutagenesis was then effected 
on these fragments in M13mp18 by the method of Kunkel (15) 
using the Muta-gene in vitro mutagenesis kit (Bio-Rad Laborato- 
ries, Richmond, VA). Mutated c~1 and o~2 exons were subcloned 
back into the 3.9-kb HLA-B27/pUC19  construct  on a  1.8-kb 
EcoKI/DralII fragment, and mutated c~3 exons were subcloned as 
a 1.8-kb DralII/BstXI fragment. 
Mutant HLA-B27  genes were then subcloned into pHEBO (16) 
as a 4.0-kb HindlII (in the 3' polylinker)/FspI (150 bp 5' in the 
pUC19 sequence) fragment, pHEBO was prepared by digestion 
with SalI, blunt-ended with Klenow DNA polymerase  I, and diges- 
tion with HindlII, before gel purification. Mutant genes were elec- 
troporated into CIR cells as previously described, and selection 
with Hygromycin was initiated 3 d later (17, 18). Mutant genes 
were verified by DNA sequencing. 
FACS  |  Analysis.  Levels  of cell surface HLA class I expression 
of all cell lines was determined within 72 h of the performance 
of both  peptide binding  and  CTL assays. This  was  done by 
FACScan  |  analysis,  using fluorescein-conjugated  antibodies  W6/32 
and PA2.6 (both monomorphic anti-HLA class I antibodies), ME1 
(anti-HLA-B27, B7,  and  Bw42) and  B27M1 (anti-HLA-B27) 
(19-21). In addition, CD8 expression by all CTL lines was verified 
by FACScan  |  using fluorescein-conjugated  antibodies OKT4 (anti- 
CD4) and OKT8 (anti-CD8). 
Synthetic Peptides.  A peptide (SRYWAIRTRSGG)  correspond- 
ing to the sequence of influenza A nucleoprotein  (383-394) (NP1)  1 
(22) was  synthesized by the  solid phase method  using  Fmoc 
chemistry. 
Generation ofAutologous CTL.  PBL from the HLA-B27-positive 
individuals were stimulated in primary culture  with 5 #g/ml 
of  (NP1) peptide  in  RPMI  1640 supplemented with  2-mM 
r-glutamine, 10% FCS (Hyclone Laboratories,  Logan, UT). After 
1 wk, cultures were restimulated with 5 x  10  s irradiated (10,000 
tad) autologous EBV-transformed  cells  plus 5/zg/ml NP1, and were 
supplemented with T cell-conditioned medium every  7 d (23) with 
either the autologous EBV cell line or HOM2 plus NP1 peptide. 
Generation ofAllogeneic CTL.  PBL from a normal donor WG 
were cultured with irradiated (10,000 tad) B27CIR cells in RPMI 
1640 supplemented with 10% FCS and 2 mM glutamine. After 
7 d, the cultures were restimulated with a different  irradiated  HLA- 
1Abbreviation used in this paper: NP1, influenza  A nucleoprotein. 
B27-positive EBV-transformed  cell  line and were supplemented  with 
T cell conditioned medium (23). After 3 wk of culture, the line 
was cloned by limiting dilution (24). 
Assay of CTL.  CTL activity was measured using a standard 
4-h SlCr release assay (23). Unless otherwise noted, target cells 
were incubated for 2 h with 200/zCi  of SlCr. Targets were then 
washed three times, counted, and plated in the presence of I or 
2/zg/ml NP1 for the duration of the assay. 
Binding Assay.  Peptide  NP1 was iodinated by the Chloramine 
T method and free 12sI separated from the iodinated peptide by 
means of a Sep-pak C18 column as previously described (25). In 
the experiment shown in Fig. 2 a, 200/~g NP1 was iodinated with 
6.5 mCi 125I and in that shown in Fig. 2 b, 20 #g was iodinated 
with 2 mCi 12sI. 
nSI-NP1 peptide was added to 500-/zl aliquots of 2.5  x  106 cells 
and incubated for 6 h at 37~  The cells were then washed, lysed, 
and the HLA-class I molecules  immunoprecipitated  with the W6/32 
antibody as previously  described (25). The amount of bound pep- 
tide  was  then  assessed by  measuring  the  12si radioactivity 
coprecipitated with the HLA class I molecules using a 1260 Multi 
gamma counter (LKB Instruments,  Inc., Gaithersburg, MD). 
Results 
Conservation of the B Specificity Pocket among HLA-B27 Sub- 
types.  The 2.6-A refined crystallographic  structure of HLA- 
A2 reveals six specificity pockets (labeled A-F) located in the 
peptide binding groove, which are thought to interact with 
amino acid side chains of  bound peptides (Fig. 1 a) (11). Com- 
parison of the sequences of the known HLA-B27 subtypes 
shows that variation between the subtypes occurs in five of 
the six pockets: A, C, D, E, and F (Table 1).  In contrast, 
the 10 residues  comprising the core of the B pocket (posi- 
tions 9,  24,  34,  45,  and 67)  and its environs (positions 7, 
63, 66, 70, and 99) are totally conserved among the subtypes 
(Table 2)  and the HLA-B27 combination of 10 residues  is 
not found in the B pocket of any other HLA class I sequence. 
This finding is significant as the B pocket is highly poly- 
morphic in all classical class I heavy chains,  especially in the 
products of the HLA-B locus, strongly suggesting that the 
B pocket has been actively conserved throughout the recent 
evolution of HLA-B27 (Table 2). 
Mutagenesis of the B Pocket of HLA-B27.  Conservation of 
the B pocket among subtypes suggests its structure is vital 
to the function of the HLA-B27 molecule. To test this hy- 
pothesis, HLA-B27 point mutants with changes at positions 
9,  45,  and 67 in the B pocket and position 70 at its rim, 
were derived.  Further mutants with substitutions at posi- 
tions 71 and 77 (o~1 domain), 97 (oe2 domain), and at posi- 
tion 227 (c~3 domain) were included for comparison (Table 
3).  In each case, the amino acid introduced by mutagenesis 
was one that occurs naturally in other HLA class I molecules 
(see Table 2).  Mutant genes were electroporated into C1R 
cells (17), and expression assessed with the monomorphic anti- 
HLA class I mAb W6/32, as well as with the anti-HLA- 
B27 antibodies ME1  and B27M1  (19-21).  Comparable ex- 
pression of each mutant was detected with all three antibodies, 
with the exception of the 45K mutant, which was detected 
at levels 12-15-fold lower than wild-type with ME1 and was 
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Figure  1.  Mapping  the polymorphic and conserved 
residues of the HLA-B27 subtypes in terms of the specificity 
pockets described in the x-ray crystallographic structure 
of HLA-A*0201. (a)  Specificity pockets A-F  of HLA- 
A*0201, as described by Saper et al. (reproduced fromJ. 
MoL Biol., 1991, by copyright permission of/~xademic  Press 
Limited,  219:277-319). (b) HLA-B27 subtype polymor- 
phisms (solid areas) and B pocket conserved residues (shaded 
areas) mapped onto the ribbon structure of HLA-A*0201, 
as described by Bjorkman  et al.  (9). 
undetectable with B27M1, and the 67Y mutant, which was 
not detectable with any of the antibodies (Table  3). Electropo- 
ration was repeated on at least three occasions with similar 
results. Lysine  at position 45 occurs naturally in many HLA-B 
locus  products including HLA-B*4001, B'4002,  B'4101, 
B'4401,  B'4701,  and B'4901,  and tyrosine at position 67 
occurs in HLA-B*0701, B'4201, and B'4601 (12). Clearly, 
expression of the HLA-B27 molecule is sensitive to muta- 
tions within the B pocket, however the finding that the 45M, 
67A, and 67S mutants were expressed  demonstrates that some 
mutations are permissible at these positions. 
Influenza Nucleolorotein Peptide (383-394) Binding to Mutant 
HLA-B27 Molecules.  NP1 (383-394) is recognized by CTL 
when bound and presented by HLA-B*2705 molecules (22). 
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Furthermore, we have shown that radioiodinated-NPl binds 
directly to a large proportion of cell surface HLA-B*2705 
molecules in a peptide- and aUele-specific  fashion in culture 
(25). We therefore tested the effects of point mutations in 
the B pocket of HLA-B*2705 on the binding of the NP1 
peptide. The results show that all mutations within the B 
pocket (9Y; 45M; 67A; and 67S) diminish peptide binding 
(Fig. 2). These effects were seen at two different peptide con- 
centrations  -  5/zg/ml (Fig. 2 a) and 50/~g/ml (Fig. 2 b), 
and ~>90% inhibition of  binding was observed. The 70Q mu- 
tation at the rim of the B pocket,  and also the 227K and 
77S mutations had no effect on peptide binding.  The 97R 
mutation,  on  the other hand,  also decreased binding by 
~>90%. Surprisingly, the mutation at position  71, a residue Table  1.  HLA-B27 Subtype Polymorphisms Mapped to Specificity Pockets as Defined in the 2.6-flt Refined Structure of HLA-A2 
Amino acid residues 
59  74  77  80  81  97  113  114  116  131  152 
Pocket  A  C  F  F  F  C/E  D/E  F  E 
B'2701  Tyr  Tyr  Asn  Thr  Ala  Asn  Tyr  His  Asp  Ser  Val 
B'2702  -  Asp  -  Ile  ....... 
B'2703  His  Asp  Asp  -  Leu  ...... 
B'2704  -  Asp  Ser  -  Leu  .....  Glu 
B'2705  -  Asp  Asp  -  Leu  ...... 
B'2706  -  Asp  Ser  -  Leu  -  -  Asp  Tyr  -  Glu 
B'27"HS"  -  Asp  Asp  -  Leu  Ser  His  Asn  Tyr  Arg  - 
The table displays only the residues that differ among the seven subtypes of HLA-B27, and the pockets (A-F) to which they map in the 2.6-A 
refined structure of HLA-A2. 
that  is not  thought  to  directly  contribute  to  the  peptide 
binding groove, reproducibly reduced binding by as much 
as 70%. 
NPl-specific CTL Lysis of  HLA-B*2705 Point Mutants.  We 
next tested whether recognition of HLA-B27 by NPl-specific 
CTL was similarly affected by point mutations in the B pocket. 
CTL lines generated from HLA-B*2705-positive donors were 
shown to be both peptide- and allele-specific by their require- 
ment for the presence of NP1 for lysis,  and their inability 
to lyse cell lines bearing  other HLA-B27 subtypes (HLA- 
B'2701,  02,  04,  and 06)  (Fig.  3). 
Peptide-specific lysis of cells expressing point mutants of 
HLA-B*2705 was tested using CTL lines from two donors, 
RB and DB (Fig. 4). The 67A and 67S mutants,  which did 
not bind peptide (Fig. 2), were not lysed by NPl-specific CTL. 
The 70Q mutation at the rim of the B pocket, which did 
not affect the extent of NP1 peptide binding,  reduced lysis 
by both CTL lines by about 50%.  The 9Y and 45M mu- 
tants,  which bound NP1 peptide poorly, were lysed about 
50% as well as wild-type HLA-B*2705-bearing  cells by the 
DB CTL line.  This latter result suggested that the 45M and 
9Y mutations do not abrogate binding, but reduce it to below 
the limit of detection in the binding assay, which we esti- 
mate to be about 1,000 peptide molecules/cell. This hypoth- 
esis was tested in two ways. First, we examined the require- 
ment for the presence of NP1 peptide throughout  the 4-h 
time period of the CTL assay. Cells expressing the 45M and 
9Y mutants and control target cells were cultured overnight 
in the presence of NP1 peptide to allow a steady-state level 
of peptide binding to be reached,  and then washed thoroughly 
before adding CTL and, to half of the assay, additional NP1 
peptide. Cells expressing wild-type HLA-B*2705 were lysed 
equally well, regardless of the presence or absence of NP1 
during the CTL assay, and both the 45M and 9Y mutants 
were lysed less well when NP1 was not included throughout 
the 4-h duration of the 51Cr release  assay (Fig.  5). Second, 
titration revealed that optimum lysis of cells expressing the 
45M and 9Y mutants of HLA-B* 2705 required, respectively, 
50 and 20 times more NP1 peptide in the assay, when com- 
pared with wild-type HLA-B*2705 (data not shown). These 
results indicate the kinetics of dissociation  and/or  associa- 
tion of the NP1 peptide with the wild-type and mutant HLA- 
B27 molecules are significantly different, with the mutants 
having a lower affinity for peptide. This is compatible with 
the conclusion that NP1 binds to the mutant HLAoB27 mol- 
ecules at a level that is sufficient to trigger CTL, hut is unde- 
tectable in  the binding  assay (29,  30). 
The 45M mutation had a surprising effect on recognition 
of HLA-B27 by the RB CTL line.  This CTL line lysed cells 
expressing the 45M mutant  in a NPl-peptide independent 
fashion (Fig.  5 b). As the amino acid at position 45 is not 
assigned to interact directly with the CTL TCR, the impli- 
cation of this observation is that the mutation alters the mol- 
ecule in such a manner that an endogenous peptide bound 
to the 45M mutant or empty 45M molecules, resembles the 
complex of wild-type HLA-B*2705 and NP1  peptide  (9). 
Point mutations not in the B pocket also had diverse effects 
upon CTL recognition.  The substitution of lysine at posi- 
tion 227 in the ol3 domain prevents CD8 binding (18, 31). 
Cells expressing the 227K mutant were not lysed by either 
CTL line,  demonstrating  their CD8 dependence.  The 71T 
mutation,  on the other hand,  abrogated recognition by the 
DB CTL line and decreased that of the RB CTL line by 60%, 
implying residues with side chains not assigned to interact 
with either peptide or TCR can affect both peptide binding 
and CTL recognition.  The 77S mutation, like the 70Q mu- 
tant,  did not affect the amount of peptide binding but did 
reduce CTL recognition by about 50%, and the 97R mutant 
neither bound significant amounts of peptide, nor was lysed 
by the CTL lines. 
In conclusion, these results indicate the 67A, 67S, and 97R 
mutations reduce CTL recognition by abrogating NP1 pep- 
tide binding.  The 9Y, 45M, and 71T mutations reduce the 
extent of peptide binding and have variable effects on T cell 
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9  24  34  45  67  7  63  66  70  99 
B* 2701,02,03,04,05,06,"HS"  H  T  V  E  C  Y  E  I  K  Y 
B*3801,B*3901,B* 1401,02  Y  S  ....  N  -  N  - 
B*0801  D  S  -  -  F  -  N  -  N  - 
B*4201,B*0701  Y  S  -  -  Y  -  N  -  Q  - 
B'4401,02  Y  -  -  K  S  -  -  -  N  - 
B72  Y  S  -  K  S  -  -  -  N  - 
B'4701  -  -  -  K  S  -  -  -  N  - 
B*4901,B*4001,02,B*4101  -  -  -  K  S  -  -  -  N  F 
B53,B*3501,B78,B*5101  Y  A  -  T  F  -  N  -  N  - 
B'5201  Y  A  -  T  S  -  -  -  N  - 
B'5801  Y  A  -  T  M  -  -  N  S  - 
B* 5701  Y  A  -  M  M  -  -  N  S  - 
B'3701  -  S  -  T  S  -  -  -  N  S 
B*  1801  -  S  -  T  S  -  N  -  N  - 
B'1301,02  Y  -  -  M  S  -  -  -  N  - 
B'4601  Y  A  -  M  Y  -  -  K  Q  - 
A*0201,02,03  F  A  -  M  V  -  -  K  H  - 
A*0207  F  A  -  M  V  -  -  K  H  C 
A*0101,A*3201  F  A  -  M  V  -  -  N  H  - 
A*0301,02,A*3001  F  A  -  M  V  -  -  N  Q  - 
A*0206,05  Y  A  -  M  V  -  -  K  H  - 
A*0210  Y  A  -  M  V  -  -  K  H  F 
A*0208  Y  A  -  M  V  -  -  N  H  - 
A*6901,A*6801,02  Y  A  -  M  V  -  N  N  Q  - 
A'2401  S  A  -  M  V  -  -  K  H  F 
A*0101  F  A  -  M  M  -  -  N  H  - 
Cw*0101  F  S  -  G  Y  -  -  K  Q  C 
Cw*0601  D  S  -  G  Y  -  -  K  Q  - 
Cw*0201,Cw*0501,Cw*1101  Y  A  -  G  Y  -  -  K  Q  - 
Cw*0301  c  A  -  G  Y  -  -  K  Q  - 
HLA-E  -  S  -  M  A  -  -  S  T  H 
HLA-F  S  A  L  M  A  E  T  Y  N  N 
HLA-G  S  A  -  M  T  -  -  N  H  I 
The table shows the 10 amino acid residues that influence  the nature of the B pocket in HLA-A2 and how they vary among 61 HLA class I sequences. 
Residues in the vicinity of the rim of the pocket are shown in bold print. All of the HLA sequences  are from Zemmour and Parham (26),  except 
for the HLA-B27  subtypes (12-14,  27,  28). 
recognition. The 700,  77S, and 227K mutations do not alter 
peptide  binding,  but  do  affect  recognition by  T  cells. 
AUoreactive  CTL  Recognition  of HLA-B*2705  Point Muta- 
tions.  To  see how  point  mutations  affected recognition by 
CTL  of different specificity, we analyzed the lysis of targets 
expressing the HLA-B*2705 mutants by an anti-HLA-B*2705 
alloreactive CTL  line,  and by five clones derived from it by 
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limiting dilution.  Lysis by the CTL  line and one done  was 
unaffected by any of the mutations. Four of five clones failed 
to lyse the 45M  mutant,  and one done  failed to lyse the 9Y 
mutant  and another the 77S mutant.  Thus, with  the notable 
exception of the methionine mutation at position 45, aUoreac- 
tire CTL  are relatively insensitive to the point mutations we 
derived. Table 3.  List of Mutations and Their Expression on  Transfected CIR  Cells 
Expression 
Name  Wildtype  Mutant  W6/32  ME1  B27M1  Saline 
CIR  174  5  4  4 
B27C1R  1,456  1,234  276  4 
9Y  His  Tyr  833  642  127  4 
45M  Glu  Met  1,443  1,195  256  4 
45K  Glu  Lys  278  94  4  4 
67Y  Cys  Tyr  201  12  4  4 
67A  Cys  Ala  1,284  998  252  4 
67S  Cys  Ser  1,235  1,056  246  4 
70Q  Lys  Gln  1,430  1,132  156  4 
71T  Ala  Thr  1,380  653  54  4 
77S  Asp  Ser  1,355  1,152  339  4 
97R  Asn  Arg  1,216  1,034  90  4 
227K  Asp  Lys  1,132  1,132  196  4 
The table lists the 11 HLA-B*2705 mutations studied, and the nature of the mutation made. Expression  was assessed by FACScan  |  analysis  using 
the antibodies  W6/32 (monomorphic  anti-HLA class I); ME1 (anti-HLA-B27, B7, and B42); and B27M1 (anti-HLA-B27) or saline.  Data are shown 
as the mean fluorescence channel for each sample. Results obtained for the poorly expressed 67Y and 45K mutants are shown in bold print. 
Discussion 
These experiments reveal a major role for the residue at 
position 45, and the B pocket in general, in HLA-B27 func- 
tion (Table 4). Initially we observed that replacing the nega- 
tively charged glutamic acid residue at position 45 with posi- 
tively charged lysine (as found in HLA-B*4001,  B'4002, 
B'4101,  B'4401, B'4701, and B'4901) resulted in a 12-15- 
fold decrease in cell surface expression, and the more conser- 
vative change to methionine (as found in HLA-A locus prod- 
ucts) was expressed  well. However, the 45M mutation greatly 
reduced the binding affinity for a known HLA-B*2705 binding 
peptide (NP1), although not to the point where CTL recog- 
nition was eliminated.  Two further observations suggested 
that  the 45M  mutation also affected presentation  of en- 
dogenously  processed peptides. First, we found that the 45M 
mutant is recognized by the NPl-peptide-specific RB CTL 
line in a peptide-independent fashion, and second, it abrogated 
recognition by four of five alloreactive clones, and no other 
mutation affected recognition by more than a single clone. 
As the residue at position 45 is not assigned to interact with 
the TCR (9-11), and since alloreactive clones are often de- 
pendent on the nature of the endogenously bound peptide 
(32), these findings are best explained by an indirect effect 
of the 45M mutation on the nature or conformation of the 
endogenous peptide,  such that it mimics the HLA-B*2705 
molecule complexed to NP1 peptide, and is no longer recog- 
nized by the majority of alloreactive clones. 
The importance of the peptide/B pocket interaction is fur- 
ther substantiated  by the finding that mutations of other 
residues in the B pocket also markedly affect HLA-B27 func- 
tion. Relatively conservative changes at positions  67 and 9 
(67S, 67A, and 9Y) decreased  NP1 peptide binding by >90%. 
In the case of the mutations at position 67, there was a con- 
comitant loss of NPl-specific CTL recognition of the mu- 
tant HLA-B*2705 molecules, suggesting an absolute loss of 
peptide binding, and the mutation at position 9 only decreased 
the affinity of binding as NPl-specific CTL, which still rec- 
ognized the mutant in a peptide dependent fashion. 
Furthermore, we found that changing cysteine at position 
67 to tyrosine caused a loss of HLA-B*2705 expression in 
C1R cells. Tyrosine at this position is found in HLA-B*0701, 
B'4201, and B'4601, and is predicted to block access to the 
B pocket (10). That two mutations (45K and 67Y) which 
radically alter the B pocket lead to a decrease in cell surface 
expression is remarkable. We favor the explanation that there 
is a relative lack of endogenous peptides able to bind these 
mutant molecules with sufficient affinity to stabilize their 
cell surface expression, although other possibilities cannot 
be formally excluded. It is interesting that E1-Zaatari et al. 
(33) showed that the 67Y mutant molecule is expressed in 
mouse L cells, albeit with a loss of the overlying ME1 anti- 
body epitope. We confirmed these results on transfecting our 
67Y mutant construct into human-flzm expressing L cells 
(data not shown).  These findings may be explained by the 
presence of a endogenous peptide in mouse, and not human 
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Figure 2.  12SI-NPl binding to HLA-B*2705 mutant CIK cells. Pep- 
tide binding to C1R, B27CIR, and HLA-B*2705 mutant molecules after 
culture of C1R transfectants expressing these molecules in the presence 
of either  (a) 50 pg/ml or (b) 5 #g/ml of 12SI-NP1. 
cells,  that  is  able  to  bind and  stabilize  the 45M  mutant 
molecule. 
That the residue at position 45 plays a major role in HLA- 
B'2705 function can be explained in terms of the structure 
of HLA-B* 2705, modeled on the known structures of HLA- 
A*0201 and HLA-A*6801 (9-11). In these molecules, the core 
of the B pocket is formed by hydrophobic residues  (9F or 
Y; 24A; 45M; 67V and 34V) and the pocket is thought to 
bind either a leucine or isoleucine side chain. Site-directed 
mutagenesis studies of HLA-A*0201 reveals that mutations 
in the B pocket also markedly affect peptide-specific and al- 
loreactive CTL recognition (34). In comparison, most of the 
residues  lining the core of the B pocket in HLA-B27 are 
hydrophilic (9H, 24T, and 67C) with the negatively charged 
45E side chain situated at the apex of the pocket. This has 
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led to the suggestion that the B pocket may bind a positively 
charged side-chain (e.g.,  histidine, arginine,  or lysine) that 
forms a salt bridge with the 45 glutamate side chain (10). 
Such a salt bridge may drastically increase the binding affinity 
of the side chain in the pocket, and effectively anchor the 
peptide in the groove. Mutations at position 45 would pre- 
vent the formation of the salt bridge and decrease the affinity 
of peptide binding without affecting the conformation of the 
bound peptide. Our finding that NPl-peptide binding to the 
45M mutant could not be detected in the binding assay, yet 
was detected by NPl-peptide specific CTL,  supports this 
model. Mutations that dramatically affect peptide binding 
affinity would also affect endogenous peptide selection  by 
HLA-B*2705. Again, this is supported by our finding that 
the 45M mutant had a major effect on alloreactive CTL rec- 
ognition. 
Mutations outside of the B pocket also had diverse effects 
on HLA-B27 function and dearly showed that the B pocket 
is not the only feature of the HLA-B27 groove that deter- 
mines binding and presentation of the NP1 peptide. Indeed, 
even changing a residue that is not assigned to interact with 
either the TCR or the peptide (threonine for the natural ala- 
nine at position 71) reduced peptide binding and abrogated 
recognition by the DB NPlospecific CTL line. This residue 
is polymorphic in the products of HLA-B locus genes and 
clearly must have an indirect effect on peptide binding and 
presentation, probably by affecting the side chain conforma- 
tion of adjacent amino acid residues that impact on the binding 
groove.  Next, we found that changing the asparagine res- 
idue for aspartate at position 97 both abrogated NP1 binding 
and NPl-specific CTL recognition, suggesting an absolute 
loss of binding. Asparagine at position 97 forms part of the 
core of both the C  and E pockets, and our results  suggest 
that interactions with these pockets may also critically affect 
peptide binding. Mutations at the rim of the B pocket (70Q) 
and the side wall of the F pocket (77S), on the other hand, 
had no affect on NP1 peptide binding but did reduce NP1- 
specific CTL recognition. This implies that these residues 
may not be involved in determining which peptides bind to 
HLA-B*2705, but do affect T cell recognition, probably by 
changing the conformation of the peptide in the groove. 
In these studies, widely different results were obtained with 
the various functional assays used to analyze the point mu- 
tants of HLA-B*2705. The NPl-peptide binding assay was 
very sensitive to changes in the amount and affinity of pep- 
tide binding to HLA-B*2705, but was a poor indicator of 
low-level binding. Peptide-specific CTL detected weak pep- 
tide binding but gave no indication of subtle changes in pep- 
tide binding unless careful titrations of limiting amounts of 
peptide were performed. Thus the two assays complement 
each other by their differing ranges of sensitivity.  In con- 
trast, aUoreactive CTL were generally insensitive to the point 
mutations we derived, with the marked exception of the 45M 
mutant. These findings may be explained in terms of the 
different reactivities of peptide-specific and aUoreactive CTL. 
Epitopes on both the presenting class I molecule and endog- 
enous peptide(s) contribute to the alloantigen, and recogni- 
tion by peptide-specific  CTL depends on bound peptide. u)  -=.. 
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Table  4.  Summary  of Functional  Analyses  of Native  and Mutant  HLA-B*2705-transfected  C1R  Cells 
Figure  3.  CTL  lysis  of HLA- 
B~  cells is peptide and allele 
specific. (a and b) Lysis of  either CIR 
(squares) or B27CIR (circles)  cells in 
the presence (open symbols)  or ab- 
sence (solid symbols) of I/zg/ml NP1 
peptide by the CTL lines (a) DB or 
(b) RB at  various E/T  ratios.  (c) 
Lysis of B27CIR cells by RBCTL 
in the presence of various concen- 
trations  of NP1  peptide  at  E/T 
ratios of 10:1 (open circles), 5:1 (solid 
circles), 2:1  (open squares),  and  1:1 
(solid squares). (d) Lysis of naturally 
occurring  HLA-B27  subtypes  by 
RBCTL in the presence of 1/~g/ml 
NP1 peptide (solid columns)  and in 
the absence of  peptide (open columns) 
at an E/T of  5:1. Similar results were 
obtained at E/T ratios of 10:1, 2:1, 
and 1:1. Full tissue types of HLA- 
B27  subtype  lines  are  given  in 
Materials and Methods. 
RBCTL  DBCTL 
Allo-CTL 
Name  Expression  NP1  binding  + NP1  -  NP1  + NP1  -  NP1  clones 
CIR  ......  0/5 
B27CIR  +++  +++  +++  -  +++  -  5/5 
9Y  +  +  +  -+  +  +  -  +  +  -  4/5 
45M  +++  -  +++  ++  ++  -  1/5 
45K  +  ND  ND  ND  ND  ND  ND 
67Y  -  ND  ND  ND  ND  ND  ND 
67A  +  +  +  .....  5/5 
67S  +  +  +  .....  5/5 
70Q  +  +  +  +  +  +  +  +  -  +  +  -  5/5 
71T  +  +  +  +  +  -  -  -  5/5 
77S  ++  +  +  +  +  +  +  -  +  +  +  -  4/5 
97R.  +  +  +  .....  5/5 
227K  +  +  +  +  +  +  ....  4/5 
The table summarizes the data shown in Table 3 and Figs. 2, 4, and 6.  ( +  +  + ) A resuh >70% of the wild-type, ( +  + ) 30-70%, and ( + ) <30% 
of the result with wild-type B27CIIk cells. The last column shows the number (out of five) of alloreactive CTL clones that lysed the given HLA- 
B'2705  mutant at levels  >10%  of the lysis of wild-type B27CIR. cells. 
816  Conserved B  Anchoring B  ("45")  Pocket of HLA-B27 a  ,01  DB CTL  a  100 
.r 
r 
._1 
0 
r 
r 
O. 
r/) 
o~ 
b 
30 
20 
10 
80 ￿84 
rm  ~1"  oJ 
m 
o 
Q. 
oO 
60. 
40, 
20 ￿84 
RB CTL 
o,I 
C1 R  Transfectants 
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AUoreactive CTL may therefore be less sensitive than peptide- 
specific CTL to subtle changes in the conformation of the 
bound peptide induced by point mutations within the groove. 
Indeed, Calvo et al. (35) reported similar results  from their 
analysis of a different set of HLA-B* 2705 point mutants with 
20 alloreactive  CTL clones. They found that only one mu- 
tant, in their case, that at position 152, affected most of the 
clones. These results suggest that certain residues within the 
peptide binding groove, such as those at position 45 and 152, 
play  a dominant  role in determining  allorecognition. 
Although  some point mutations  (45K and 67Y)  appear 
to alter the class I molecule so much as to prevent expression 
altogether, the NPl-specific CTL data suggests that most point 
mutations compatible with cell surface expression alter rec- 
ognition by directly affecting bound peptide.  Previous results 
Figure 5.  45M and 67Y mutants cells require the presence of NP1 pep- 
tide for optimal lysis. 45M (a), 9Y (b), and control B27-C1R (c) cells were 
incubated for 14 h in the presence of 1/zg/ml NP1 and then washed three 
times. These target cells were then cultured with RB CTL at various E/T 
ratios in the presence (solid circles) or absence (open circles) of 1/zg/ml NP1 
for the standard 4-h CTL assay. Negative control cells (open squares) were 
cultured without peptide during both the preincubation and the CTL assay. 
indicated that the mechanism of the binding assay involves 
the interaction of the radiolabeled peptide with an apparently 
large number of "empty"  HLA molecules on the cell sur- 
face. The CTL data here complements these results and sug- 
gests that most point mutations  do not alter  the stability 
of the empty molecules, or the proportion of molecules that 
arrive at the cell surface empty. 
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Figure 6.  Alloreactive CTL lysis 
of  HLA-B*2705  wild-type  and 
mutant-transfected  C1R cells by the 
WG CTL line (a) and 5 WG clones, 
WG2 (b), WG3 (c), WG6 (d), WG7 
(e), and WG8 (j') at an E/T of 5:1. 
Similar results were obtained at E/T 
ratios of 10:1, 2:1, and 1:1. 
In conclusion, we have shown that B pocket is highly con- 
served among the HLA-B27 subtypes, and that it plays an 
important role in the expression of HLA-B*2705 and in the 
presentation of both endogenous and exogenous peptides. In 
light of these findings, we predict that the B pocket anchors 
an antigenic peptide amino acid side chain that will be found 
in a similar position in most endogenously-processed  pep- 
tides bound by HLA-B*2705. Furthermore, the conservation 
of the B pocket among HLA-B27 subtypes suggests that pep- 
tides bound to all of these will carry the same motif. Wiley 
and colleagues have recently solved the HLA-B27 x-ray crys- 
tallographic structure, emphasizing the importance of the B 
pocket (35a). Furthermore, they have sequenced 11 naturally 
processed peptides isolated from HLA-B27, and found that 
818 
all of these have an arginine residue at position 2 (35b). To- 
gether, these observations have implications for the associa- 
tion of HLA-B27 with Ankylosing Spondylitis, a disease  which 
is thought to be mediated by CTL that recognize a self-peptide 
presented by HLA-B27 (36). One argument against this "ar- 
thritogenic peptide" hypothesis is the finding that multiple 
subtypes (HLA-B*2702; 04, 05, and 06) are disease associated, 
and differ greatly in peptide binding, alloreactive~CTL and 
peptide-specific CTL recognition (22, 25, 37). Our findings 
suggest  that these subtypes all bind peptides with at least 
one common anchor motif, rendering it more likely that a 
single arthritogenic peptide may be presented to CTL by mul- 
tiple HLA-B27 subtypes, thereby explaining the shared dis- 
ease association. 
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